Evaluation of ranirestat for the treatment of diabetic neuropathy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 7, 2014, Pages 1051-1059

  Giannoukakis, Nick ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Aldose reductase inhibitors; AS 3021; Diabetes mellitus; Diabetic complications; Pharmacokinetics; Polyol pathway; Ranirestat

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; BIOLOGICAL MARKER; RANIRESTAT; ALDEHYDE REDUCTASE; ENZYME INHIBITOR; PYRAZINE DERIVATIVE; SPIRO COMPOUND;

ARTICLE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MEDICAL LITERATURE; MEDICAL SUBJECT HEADINGS; MEDLINE; NONHUMAN; PHARMACODYNAMICS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHIES; DRUG SCREENING; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RAT; REPRODUCIBILITY;

ALDEHYDE REDUCTASE; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DIABETIC NEUROPATHIES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MICE; PYRAZINES; RATS; REPRODUCIBILITY OF RESULTS; SPIRO COMPOUNDS;

EID: 84902511018     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.916277     Document Type: Article

References (64)

1. DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010;123(Suppl 3):S38-48
2. DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010;123(Suppl 3):S1-2
3. Freeman JS. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodiumglucose co-transporter 2 inhibitors. Postgrad Med 2013;125(3):214-26
4. Mehanna A. Antidiabetic agents: past, present and future. Future Med Chem 2013;5(4):411-30
5. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-Analysis. Ann Intern Med 2013;159(4):262-74
6. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007;67(7):997-1026
7. Nair M. Diabetes mellitus, part 1: physiology and complications. Br J Nurs 2007;16(3):184-8
8. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007;369(9575):1823-31
9. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285-93
10. Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med 2007;7(8):766-76
11. Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol 1999;9(2):369-91
12. Zochodne DW. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007;36(2):144-66
13. Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 2004;3(4):245-55
14. El-Kabbani O, Ruiz F, Darmanin C, Chung RP. Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 2004;61(7-8):750-62
15. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002;50:325-92
16. Obrosova IG, Kador PF. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr Pharm Biotechnol 2011;12(3):373-85
17. Petrash JM. All in the family: Aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci 2004;61(7-8):737-49
18. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 2012;3:87
19. Zhu C. Aldose reductase inhibitors as potential therapeutic drugs of diabetic complications. In: Oguntibeju OO, editor. Diabetes mellitus: insights and perspectives. InTech, Rijeka, Croatia; 2013. p. 17-46
20. Alexiou P, Pegklidou K, Chatzopoulou M, et al. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem 2009;16(6):734-52
21. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003;14(8 Suppl 3):S233-6
22. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000;77:S3-12
23. Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 2005;26(3):380-92
24. Gonzalez RG, Barnett P, Cheng HM, Chylack LT Jr. Altered phosphate metabolism in the intact rabbit lens under high glucose conditions and its prevention by an aldose reductase inhibitor. Exp Eye Res 1984;39(5):553-62
25. Allen DA, Yaqoob MM, Harwood SM. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. J Nutr Biochem 2005;16(12):705-13
26. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005;54(6):1615-25
27. Cohen RA. Role of nitric oxide in diabetic complications. Am J Ther 2005;12(6):499-502
28. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005;20(12):2601-4
29. Niedowicz DM, Daleke DL. The role of oxidative stress in diabetic complications. Cell Biochem Biophys 2005;43(2): 289-330
30. Nishikawa T, Kukidome D, Sonoda K, et al. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes Res Clin Pract 2007;77(Suppl 1):S41-5
31. Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007;7(3):242-8
32. Triplitt CL. New technologies and therapies in the management of diabetes. Am J Manag Care 2007;13(Suppl 2):S47-54
33. Triplitt CL. Managing diabetes in patients with diabetes of long duration. Diabetes Educ 2012;38(4 Suppl):23S-30S; quiz 31S
34. Giannoukakis N. Drug evaluation: ranirestat-An aldose reductase inhibitor for the potential treatment of diabetic complications. Curr Opin Investig Drugs 2006;7(10):916-23
35. Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drugs 2008;17(4):575-81
36. Hotta N, Sakamoto N, Shigeta Y, et al. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications 1996;10(3):168-72
37. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: A 52-week multicenter placebo-controlled doubleblind parallel group study. Diabetes Care 2001;24(10):1776-82
38. Bril V, Hirose T, Tomioka S, Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009;32(7):1256-60
39. Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004;27(10):2369-75
40. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006;29(1):68-72
41. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53(3):580-91
42. Negoro T, Murata M, Ueda S, et al. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo [1,2-A]pyrazine -4-spiro-3-pyrrolidine-1,2,3,5-tetrone (AS-3201) and its congeners. J Med Chem 1998;41(21):4118-29
43. Kurono M, Fujii A, Murata M, et al. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: A significant role of specific binding by serum albumin in the improved potency and stability. Biochem Pharmacol 2006;71(3):338-53
44. Matsumoto T, Ono Y, Kuromiya A, et al. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats. J Pharmacol Sci 2008;107(3):340-8
45. Matsumoto T, Ono Y, Kurono M, et al. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci 2008;107(3):231-7
46. Matsumoto T, Ono Y, Kurono M, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci 2009;109(2):203-10
47. Nakamura J, Lattimer SA, Greene DA. Transphosphatidylation of sugar alcohols and its implications for the pathogenesis of diabetic complications. Diabetologia 1994;37(11):1147-53
48. Kurono M, Fujiwara I, Yoshida K. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase. Biochemistry 2001;40(28):8216-26
49. Toide K, Terauchi Y, Fujii T, et al. Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDPglucuronosyltransferase 2B subfamily in human liver microsomes. Biochem Pharmacol 2004;67(7):1269-78
50. Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic nonobese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000;1(2):89-100
51. Ota A, Kakehashi A, Toyoda F, et al. Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats. J Diabetes Res 2013;2013:175901
52. Hamada Y, Kitoh R, Raskin P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes 1991;40(10):1233-40
53. Ko BC, Ruepp B, Bohren KM, et al. Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem 1997;272(26):16431-7
54. Vander Jagt DL, Hunsaker LA, Robinson B, et al. Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. J Biol Chem 1990;265(19):10912-18
55. Wang K, Bohren KM, Gabbay KH. Characterization of the human aldose reductase gene promoter. J Biol Chem 1993;268(21):16052-8
56. Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial hyperglycemia the main culprit? A mini-review. Gerontology 2013;59(3):193-8
57. Shakher J, Stevens MJ. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes 2011;4:289-305
58. Lee SS, Han HS, Kim H. A 5-yr followup nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. Pediatr Diabetes 2010;11(8):521-8
59. Fujita Y, Fukushima M, Suzuki H, et al. Short-term intensive glycemic control improves vibratory sensation in type 2 diabetes. Diabetes Res Clin Pract 2008;80(1):e16-19
60. Booya F, Bandarian F, Larijani B, et al. Potential risk factors for diabetic neuropathy: A case control study. BMC Neurol 2005;5:24
61. Klein R, Klein BE. Relation of glycemic control to diabetic complications and health outcomes. Diabetes Care 1998;21(Suppl 3):C39-43
62. Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care 1998;21(10):1749-52
63. Lloyd CE, Becker D, Ellis D, Orchard TJ. Incidence of complications in insulin-dependent diabetes mellitus: A survival analysis. Am J Epidemiol 1996;143(5):431-41
64. Suljic E, Kulasin I, Alibegovic V. Assessment of diabetic polyneuropathy in inpatient care: fasting blood glucose, HbA1c, electroneuromyography and diabetes risk factors. Acta Inform Med 2013;21(2):123-6